Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 12/20 | 0.41 |
| ▸ | CA9 | Q16790 | 12/20 | 0.41 |
| ▸ | CA1 | P00915 | 11/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1792764 | 0.97 | PTGS2 (0.44) | PTGS2PTGS1CA2CA9CA1 | |
| SCHEMBL1793830 | 0.97 | PTGS2 (0.44) | PTGS2PTGS1CA2CA9CA1 | |
| SCHEMBL1791571 | 0.96 | PTGS2 (0.43) | PTGS2PTGS1CA2CA9CA1 | |
| SCHEMBL1792126 | 0.91 | PTGS2 (0.41) | PTGS2CA2CA9CA1CA12 | |
| SCHEMBL1791780 | 0.91 | PTGS2 (0.38) | PTGS2PTGS1CA2CA9MAPT | |
| SCHEMBL1790070 | 0.90 | NTRK1 (0.40) | PTGS2PTGS1CA2CA9MAPT | |
| SCHEMBL1792081 | 0.89 | TP53 (0.39) | PTGS2PTGS1CA2CA9CA1 | |
| SCHEMBL1789966 | 0.89 | PTGS2 (0.39) | PTGS2PTGS1MAPTTP53ADORA2A | |
| SCHEMBL1789942 | 0.89 | PTGS2 (0.39) | PTGS2PTGS1CA2CA9CA1 | |
| SCHEMBL1791453 | 0.89 | PTGS2 (0.42) | PTGS2CA2CA9CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, CYP2S1, DPYD | PTGS2 491/4885PTGS1 598/4885CA2 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.